ONO 5334
Alternative Names: ONO-5334Latest Information Update: 05 Nov 2023
At a glance
- Originator Ono Pharmaceutical
- Class Osteoporosis therapies
- Mechanism of Action Bone resorption factor inhibitors; Cathepsin K inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 02 Feb 2012 Discontinued - Phase-I for Osteoporosis in Japan (PO)
- 02 Feb 2012 Discontinued - Phase-I for Osteoporosis in United Kingdom (PO)
- 02 Feb 2012 Discontinued - Phase-II for Osteoporosis in European Union (PO)